Jacqueline C. Barrientos, MD

Recommendations for applying information from clinical trials presented at oncology and hematology conferences in 2021 into routine clinical practice when managing patients with chronic lymphocytic leukemia.

OncLive® speaks with Dr. Nina Shah on some practice-changing multiple myeloma abstracts, and Dr. Jacqueline Barrientos on the latest in chronic lymphocytic leukemia.

Jacqueline C. Barrientos, MD, associate professor, The Feinstein Institute for Medical Research, Northwell Health, discusses promising agents in the treatment of patients with chronic lymphocytic leukemia.

Jacqueline C. Barrientos, MD, associate professor, The Feinstein Institute for Medical Research, Northwell Health, discusses important considerations for patients with mantle cell lymphoma.

Jacqueline C. Barrientos, MD, associate professor, The Feinstein Institute for Medical Research, Northwell Health, discusses advances in the treatment landscape for patients with chronic lymphocytic leukemia (CLL).

Jacqueline C. Barrientos, MD, associate professor, The Feinstein Institute for Medical Research, Northwell Health, discusses the role of acalabrutinib (Calquence) for patients with chronic lymphocytic leukemia (CLL).

Jacqueline C. Barrientos, MD, associate professor, The Feinstein Institute for Medical Research, Northwell Health, discusses the impact of combinations in the treatment of chronic lymphocytic leukemia.

Jacqueline C. Barrientos, MD, associate professor, The Feinstein Institute for Medical Research, Northwell Health, discusses the impact of recent combination trials for patients with chronic lymphocytic leukemia (CLL).

Jacqueline C. Barrientos, MD, associate professor, The Feinstein Institute for Medical Research, Northwell Health, discusses the role of acalabrutinib (Calquence) for patients with chronic lymphocytic leukemia (CLL).

Over the past few years, remarkable advances have been achieved in the field of chronic lymphocytic leukemia by rationally targeting pathways overexpressed and used by the malignant clone for proliferation and survival.

Jacqueline C. Barrientos, MD, associate professor, The Feinstein Institute for Medical Research, Northwell Health, discusses ibrutinib (Imbruvica) in elderly populations with CLL.

Jacqueline C. Barrientos, MD, associate professor, The Feinstein Institute for Medical Research, discusses the management of elderly patients with chronic lymphocytic leukemia (CLL).